Skip to main content

Table 7 Base case results: cost-effectiveness

From: Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia

 

FDC tablet solifenacin 6 mg + TOCAS

Tolterodine + tamsulosin

Total costs* (£)

860

959

 Difference

–

−99

QALYs*

0.840

0.836

 Difference

–

0.002

ICER*‡

–

Dominates (−£40,469)

  1. *Per patient at 1 year.
  2. ‡FDC tablet solifenacin 6 mg + TOCAS versus tolterodine + tamsulosin.
  3. FDC, fixed-dose combination; ICER, incremental cost effectiveness ratio; QALY, quality of life adjusted years; TOCAS, oral controlled absorption system (OCASâ„¢) formulation of tamsulosin.
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us